Additionally, mutations such as FLT3-ITD, NPM1, and DNMT3A not only contribute to AML pathogenesis but may also influence responses to CAR-based therapies, emphasizing the need for molecularly guided treatment strategies. Here, FLT3 is linked to acute myeloid leukemia.